ArticleMolecular cancer2017
Evaluation on the diagnostic and prognostic values of long non-coding RNA BLACAT1 in common types of human cancer.
Article in Molecular cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 65 citations in OpenAlex.
- A Novel MPT-Driven Necrosis-Related lncRNA Signature for Prognostic Prediction in Hepatocellular Carcinoma: Validation Using Organoids.Cancer medicine · 2026Article
- Promises and pitfalls of multi-cancer early detection using liquid biopsy tests.Nature reviews. Clinical oncology · 2025Review
- Urinary BLACAT1 as a non-invasive biomarker for bladder cancer.Molecular biology reports · 2023Article
- Long noncoding RNA DIAPH2-AS1 promotes neural invasion of gastric cancer via stabilizing NSUN2 to enhance the m5C modification of NTN1.Cell death & disease · 2023Article
- Review
- Identifying critical protein-coding genes and long non-coding RNAs in non-functioning pituitary adenoma recurrence.Oncology letters · 2021Article
- Long non-coding RNA AC023794.4-201 exerts a tumor-suppressive function in laryngeal squamous cell cancer and may serve as a potential prognostic biomarker.Oncology letters · 2020Article
- Knockdown of lncRNA BLACAT1 enhances radiosensitivity of head and neck squamous cell carcinoma cells by regulating PSEN1.The British journal of radiology · 2020Article
- Down-regulation of lncRNA BLACAT1 inhibits ovarian cancer progression by suppressing the Wnt/β-catenin signaling pathway via regulating miR-519d-3p.Molecular and cellular biochemistry · 2020Article
- Long Non-Coding RNA BLACAT1 Promotes the Tumorigenesis of Gastric Cancer by Sponging microRNA-149-5p and Targeting KIF2A.Cancer management and research · 2020Article
- Long Non-Coding RNA BLACAT1 in Human Cancers.OncoTargets and therapy · 2020Review
- Integrated analysis of immune-related genes in endometrial carcinoma.Cancer cell international · 2020Article
- Circulating Long Noncoding RNAs Act as Diagnostic Biomarkers in Non-Small Cell Lung Cancer.Frontiers in oncology · 2020Article
- Long-Chain Non-Coding RNA SNHG3 Promotes the Growth of Ovarian Cancer Cells by Targeting miR-339-5p/TRPC3 Axis.OncoTargets and therapy · 2020Article
- LncRNA LINC00665 Promotes Prostate Cancer Progression via miR-1224-5p/SND1 Axis.OncoTargets and therapy · 2020Article
- Long non-coding RNA BLACAT1 promotes the proliferation and invasion of glioma cells via Wnt/β-catenin signaling.Experimental and therapeutic medicine · 2019Article
- Predicting the regrowth of clinically non-functioning pituitary adenoma with a statistical model.Journal of translational medicine · 2019Article
- Clinical value of miRNA-122 in the diagnosis and prognosis of various types of cancer.Oncology letters · 2019Article
- Overexpression of the long non-coding RNATranslational cancer research · 2019Article
- Screening key lncRNAs for human lung adenocarcinoma based on machine learning and weighted gene co-expression network analysis.Cancer biomarkers : section A of Disease markers · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A growing number of evidence has indicated that long non-coding RNAs (lncRNA) may have many functions in the development and progression of cancer, and cloud serve as good diagnostic and prognostic biomarkers in cancers. However, these studies often revealed the changes of lncRNAs within a specific cancer type. Here, we focused on BLACAT1 and provided a comprehensive pan-cancer analysis to evaluate the diagnostic and prognostic values of BLACAT1. The expression data of BLACAT1 were came from the quantitative real-time polymerase chain reaction (qRT-PCR) and The Cancer Genome Atlas (TCGA) database, respectively. Our results showed that the change of serum BLACAT1 expression was similar to those in matched tissues. The expression level of BLACAT1 both in serum and tissues in multiple cancer types were significantly upregulated compared to those of matched non-cancer participants. The serum BLACAT1 had a high diagnostic performance among these 12 types of cancer. The relative AUC of serum BLACAT1 in cancer patients ranged from 0.833 to 0.967 compared to that in healthy subjects. Surprisingly, Kaplan-Meier survival analysis revealed that the high expression level of BLACAT1 was significantly associated with poor overall survival only in uterine corpus endometrial carcinoma (p = 0.002, log-rank test). These findings demonstrated that BLACAT1 could act as a non-specific diagnostic biomarker for cancers and a potential biomarker for prognosis prediction of endometrial cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.